Cell and gene ther­a­py 2.0 dom­i­nates lat­est round of biotech IPOs in scram­ble for a $300M-plus Nas­daq wind­fall

Back at the start of Jan­u­ary last year, Po­sei­da Ther­a­peu­tics thought it had an IPO-wor­thy game plan that would sell on Wall Street. In­stead, with the mar­ket in some­thing of a dys­pep­tic mood, the San Diego-based start­up with its next-gen ap­proach to cell and gene ther­a­py switched to a Se­ries C mega round and dropped the IPO.

Un­til now, while the mar­ket is run­ning red hot for all things drug-de­vel­op­ment re­lat­ed. And on Fri­day Nas­daq loaded up a new round of biotech IPOs to sell to in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.